Siggillino A - Search Results

1

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.

Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, Chiari R. Baglivo S, et al. Among authors: siggillino a. J Thorac Oncol. 2018 Aug;13(8):e145-e147. doi: 10.1016/j.jtho.2018.03.017. J Thorac Oncol. 2018. PMID: 30049377 Free article. No abstract available.

2

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. Among authors: siggillino a. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.

3

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

Ricciuti B, Metro G, Brambilla M, Ludovini V, Baglivo S, Siggillino A, Prosperi E, Chiari R. Ricciuti B, et al. Among authors: siggillino a. J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025. J Thorac Oncol. 2018. PMID: 29258673 Free article. No abstract available.

4

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maiettini D, Chiari R. Ricciuti B, et al. Among authors: siggillino a. Lung Cancer. 2018 Jun;120:70-74. doi: 10.1016/j.lungcan.2018.04.002. Epub 2018 Apr 3. Lung Cancer. 2018. PMID: 29748019

5

Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.

Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L. Ludovini V, et al. Among authors: siggillino a. J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f. J Thorac Oncol. 2011. PMID: 22052224 Free article.

6

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L. Metro G, et al. Among authors: siggillino a. Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770374

7

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report.

Metro G, Valtorta E, Siggillino A, Lauricella C, Cenci M, Ludovini V, Minenza E, Prosperi E, Ricciuti B, Rebonato A, Bassetti A, Crinò L. Metro G, et al. Among authors: siggillino a. Ecancermedicalscience. 2015 Jul 28;9:559. doi: 10.3332/ecancer.2015.559. eCollection 2015. Ecancermedicalscience. 2015. PMID: 26284123 Free PMC article.

8

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.

Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, Chiari R, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L. Ludovini V, et al. Among authors: siggillino a. Oncotarget. 2016 May 24;7(21):30561-74. doi: 10.18632/oncotarget.8723. Oncotarget. 2016. PMID: 27081700 Free PMC article.

9

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.

Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A, Rebonato A, Messina S, Crinò L, Chiari R. Baglivo S, et al. Among authors: siggillino a. Mayo Clin Proc. 2017 Aug;92(8):1304-1311. doi: 10.1016/j.mayocp.2017.03.022. Mayo Clin Proc. 2017. PMID: 28778263

10

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Metro G, Baglivo S, Siggillino A, Ludovini V, Chiari R, Rebonato A, Bellezza G. Metro G, et al. Among authors: siggillino a. Clin Drug Investig. 2018 Oct;38(10):983-987. doi: 10.1007/s40261-018-0691-8. Clin Drug Investig. 2018. PMID: 30151614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters